Open-to-Accrual Therapeutic Trials

Phase I

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


I137-102    NCT02931110

A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers C. Sportès Sandra Wall Lymphomas (B-Cell, Diffuse Large B-Cell,  Mantle Cell, Follicular, Hodgkin; Lymphosarcoma) I

KW-0761-012    NCT02301130

Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors A. Nayak Lisa Marshall
Advanced solid tumors



A Phase 1 Trial of Indoximod in Combination with Temozolomide-Based Therapy for Children with Progressive Primary Brain Tumors T. Johnson Robin Dobbins Primary Brain Tumors I
TESARO 4010-01-001   NCT02715284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Kelly Jenkins Advanced solid tumors I

Phase I/II

Phase 1-2 Study of MEDI4736 Alone or In Combination With ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Metastatic Head & Neck Cance S. Ghamande Renee Townsend Phase 1: Cervical Cancer,  HPV+ Head & Neck Cancer
Phase 2: Cervical Cancer


A phase Ib /II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer (NSCLC) who have failed immune checkpoint inhibitor Z. Hao Kelly Jenkins Non-Small Cell Lung Cancer (NSCLC) I/II

IMDZ-G142   NCT02501473 

Phase 1/2 Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma L. Bryan Sandra Wall Follicular Non-Hodgkin's Lymphoma I/II
INCB-39110-206     NCT02760485 An Open Label Phase 1/2 Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma   L. Bryan Sandra Wall Diffuse Large B-Cell Lymphoma I/II 
INO-VT-464-CL-006     NCT02580448 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer H. Boppidi Sandra Wall Advanced Breast Cancer I/II
KW-0761-014    NCT02705105 Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors A. Nayak Lisa Marshall Only open for hepatocellular carcinoma (HCC)



A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer Z. Hao Kelly Jenkins Small Cell Lung Cancer I/II
NLG-2104     NCT02077881 A Phase 1/2 Study of Indoximod in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas A. Nayak Lisa Marshall Pancreatic Cancer I/II
NLG-2106 NCT02835729 A Phase 1b/Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) J. Pantin Sandra Wall Acute Myeloid Leukemia (AML) I/II

Closed for New Patient Enrollment, Open for Current Patients

EMR 100070-001 A Phase 1, Open-Lable, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indicators (PI: Khleif)
GO29753 (formerly NLG-9191) A Phase 1 Study of GDC-0919 for Adult Patients with Recurrent Advanced Solid Tumors (PI: Khleif)
MEDI4736-1108 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors (PI: Khleif)
NLG-2102 A Phase 1/2 Study of the Combination of 1-Methyl-D-Tryptophan (Indoximod) and Temozolomide for Adults Patients with Temozolomide-Refractory Primary Malignant Brain Tumors (PI: Hao)
NLG-2103 A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Ipilimumab for Adult Patients with Advanced or Metastatic Melanoma (PI: Parikh)